Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beam Therapeutics Inc.BEAM · Entity 4227 | Director | June 04, 2025 | June 06, 2025 |
| Denali Therapeutics Inc.DNLI · Entity 1735 | Chief Medical Officer | August 12, 2025 | August 15, 2025 |
| ELI LILLY & CoLLY · Entity 2794 | EVP & Pres, Lilly Neuroscience | December 31, 2025 | January 06, 2026 |
| Royalty Pharma plcRPRX · Entity 3100 | Director | June 05, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beam Therapeutics Inc.
Report date June 04, 2025 · Filed June 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.15 · Expires 2035-06-04 | Direct | 33,662 |
Reported balance
After 2025-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-04 · Grant · Acquired 33,662 · Balance 33,662 F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.
Denali Therapeutics Inc.
Report date August 12, 2025 · Filed August 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 216,585 |
Last balance in matching sequence
After 2025-08-13 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-08-12 · Sale · Disposed 2,937 · Balance 217,391 F1: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.34 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3: Includes 128,405 Unvested RSUs. Row 2 · 2025-08-13 · Sale · Disposed 806 · Balance 216,585 F4: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted December 11, 2024. F3: Includes 128,405 Unvested RSUs. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 183,219 |
Reported balance
Holding disclosure · report date 2025-08-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 183,219 F5: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 25,000 |
Reported balance
Holding disclosure · report date 2025-08-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 25,000 F6: The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.34 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: Includes 128,405 Unvested RSUs.
F4: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted December 11, 2024.
F5: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
F6: The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.
ELI LILLY & Co
Report date December 31, 2025 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-12-31 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F2: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. F1: The restricted stock units vest in three installments, 904.631 on December 1, 2026, 932.044 on December 1, 2027, and 904.631 on December 1, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three installments, 904.631 on December 1, 2026, 932.044 on December 1, 2027, and 904.631 on December 1, 2028.
F2: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.
Royalty Pharma plc
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | Direct | 4,545 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 4,545 · Balance 4,545 F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectSee footnote | 8,558 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 8,558 F2: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.
F2: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NGM BIOPHARMACEUTICALS INC
Report date April 05, 2024 · Filed April 08, 2024
Section 16 reporting ended · disclosed 2024-04-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.69 · Expires 2033-05-09 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-05 · Disposition to issuer · Disposed 78,407 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.35 · Expires 2032-05-17 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-05 · Disposition to issuer · Disposed 24,222 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.24 · Expires 2031-06-07 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-05 · Disposition to issuer · Disposed 19,619 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.66 · Expires 2030-06-04 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-04-05 · Disposition to issuer · Disposed 39,515 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").
F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2019 Filed Jan 4, 2019 23:54 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,777 | $18.90 | $52,485.30 |
DisclosureSEC source: 0001209191-19-002289 · doc4.xml · nonDerivative · entry 6 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,777 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.56 to $19.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 23:54 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 5,775 | $5.28 | $30,492.00 |
DisclosureSEC source: 0001209191-19-002289 · doc4.xml · nonDerivative · entry 5 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · balance_after: Includes 1,894 shares acquired on May 31, 2018 and 883 shares acquired on November 30, 2018 under the Issuer's 2017 Employee Stock Purchase Plan. Read SEC document |
| January 03, 2019 Filed Nov 30, 2020 23:14 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 5,775 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-20-060793 · doc4a.xml · derivative · entry 12 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,825 Underlying: Common Stock · 5,775 shares Expires 2026-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Of the total 125,000 shares granted, 25% of the shares subject to the option vested on July 2, 2017 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| January 03, 2019 Filed Nov 30, 2020 23:14 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 5,775 | $18.90 | $109,147.50 |
DisclosureSEC source: 0001209191-20-060793 · doc4a.xml · nonDerivative · entry 7 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 178,125 F4 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.56 to $19.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| January 03, 2019 Filed Nov 30, 2020 23:14 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 5,775 | $5.28 | $30,492.00 |
DisclosureSEC source: 0001209191-20-060793 · doc4a.xml · nonDerivative · entry 6 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 183,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 23:54 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 900 | $20.24 | $18,216.00 |
DisclosureSEC source: 0001209191-19-002289 · doc4.xml · nonDerivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 142,615 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.13 to $20.42 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F5 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 23:54 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,875 | $19.43 | $94,721.25 |
DisclosureSEC source: 0001209191-19-002289 · doc4.xml · nonDerivative · entry 3 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 143,515 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.11 to $20.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F5 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| January 02, 2019 Filed Nov 30, 2020 23:14 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 5,775 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-20-060793 · doc4a.xml · derivative · entry 11 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,600 Underlying: Common Stock · 5,775 shares Expires 2026-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Of the total 125,000 shares granted, 25% of the shares subject to the option vested on July 2, 2017 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| January 02, 2019 Filed Nov 30, 2020 23:14 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 900 | $20.24 | $18,216.00 |
DisclosureSEC source: 0001209191-20-060793 · doc4a.xml · nonDerivative · entry 5 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 178,125 F4 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.13 to $20.42 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| January 02, 2019 Filed Nov 30, 2020 23:14 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,875 | $19.43 | $94,721.25 |
DisclosureSEC source: 0001209191-20-060793 · doc4a.xml · nonDerivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 179,025 F4 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.11 to $20.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| January 02, 2019 Filed Nov 30, 2020 23:14 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 5,775 | $5.28 | $30,492.00 |
DisclosureSEC source: 0001209191-20-060793 · doc4a.xml · nonDerivative · entry 3 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 183,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 22:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 400 | $19.16 | $7,664.00 |
DisclosureSEC source: 0001209191-18-061334 · doc4.xml · nonDerivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 148,390 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.15 to $19.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F5 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 22:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 17,100 | $18.43 | $315,170.10 |
DisclosureSEC source: 0001209191-18-061334 · doc4.xml · nonDerivative · entry 3 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 148,790 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.07 to $18.87 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F5 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| December 03, 2018 Filed Nov 30, 2020 23:13 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-20-060791 · doc4a.xml · derivative · entry 6 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,375 Underlying: Common Stock · 17,500 shares Expires 2026-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Of the total 125,000 shares granted, 25% of the shares subject to the option vested on July 2, 2017 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 03, 2018 Filed Nov 30, 2020 23:13 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 400 | $19.16 | $7,664.00 |
DisclosureSEC source: 0001209191-20-060791 · doc4a.xml · nonDerivative · entry 5 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 178,125 F4 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.15 to $19.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| December 03, 2018 Filed Nov 30, 2020 23:13 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 17,100 | $18.43 | $315,170.10 |
DisclosureSEC source: 0001209191-20-060791 · doc4a.xml · nonDerivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 178,525 F4 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.07 to $18.87 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| December 03, 2018 Filed Nov 30, 2020 23:13 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 17,500 | $5.28 | $92,400.00 |
DisclosureSEC source: 0001209191-20-060791 · doc4a.xml · nonDerivative · entry 3 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 195,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 22:31 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 17,500 | $18.07 | $316,156.75 |
DisclosureSEC source: 0001209191-18-059267 · doc4.xml · nonDerivative · entry 3 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 165,890 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F5 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| November 15, 2018 Filed Nov 30, 2020 23:12 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 12,235 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-20-060790 · doc4a.xml · derivative · entry 5 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,875 Underlying: Common Stock · 12,235 shares Expires 2026-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Of the total 125,000 shares granted, 25% of the shares subject to the option vested on July 2, 2017 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 15, 2018 Filed Nov 30, 2020 23:12 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 17,500 | $18.07 | $316,156.75 |
DisclosureSEC source: 0001209191-20-060790 · doc4a.xml · nonDerivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 178,125 F4 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| November 15, 2018 Filed Nov 30, 2020 23:12 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 12,235 | $5.28 | $64,600.80 |
DisclosureSEC source: 0001209191-20-060790 · doc4a.xml · nonDerivative · entry 3 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 195,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 17,500 | $21.72 | $380,100.00 |
DisclosureSEC source: 0001209191-18-054050 · doc4.xml · nonDerivative · entry 3 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 183,390 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.36 to $22.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F5 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 17,500 | $19.05 | $333,375.00 |
DisclosureSEC source: 0001209191-18-049912 · doc4.xml · nonDerivative · entry 3 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 200,890 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.65 to $19.51 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F5 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:44 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 17,500 | $18.04 | $315,700.00 |
DisclosureSEC source: 0001209191-18-049119 · doc4.xml · nonDerivative · entry 3 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 218,390 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F5 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:43 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 11,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-048028 · doc4.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,286 Underlying: Common Stock · 11,286 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 50% of the restricted stock units shall vest on August 20, 2019 and the remaining 50% shall vest on August 20, 2020, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 50% of the restricted stock units shall vest on August 20, 2019 and the remaining 50% shall vest on August 20, 2020, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 26, 2018 Filed Mar 1, 2018 00:57 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $22.16 | $0.00 |
DisclosureSEC source: 0001209191-18-014731 · doc4.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2028-02-25 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on February 26, 2019 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.